Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04525014
Title RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors EpicentRx, Inc.

brain cancer

Advanced Solid Tumor

spinal cancer


Irinotecan + RRx-001 + Temozolomide

Age Groups: adult | child
Covered Countries USA

No variant requirements are available.